Rebecca Lambert is the Founder and Executive Chairman of the Board of NED Biosystems, Inc. NED’s lead drug candidate NED-170, is the first therapy to affect multiple pathways within each of the five major processes which drive all cancers. NED-170 is oral, lacks toxicity/side effects, and has shown promising signal in 26 observational patients. She is also the Founder, President, and Director of ASSIST Medical Research Foundation (ASSIST), whose mission is to accelerate translational therapies and diagnostics for complex chronic diseases driven by angiogenesis. Both NED and ASSIST are the result of a decade-long effort to utilize big data research to advance disease treatments. These efforts began to support Ms. Lambert’s sister’s battle with terminal sarcoma.
Ms. Lambert has one patent issued. The NED-170 cancer therapy patent is pending and been assigned to NED Biosystems.
Ms. Lambert has led capital raising efforts for Wall Street firms and created the largest multi-channeled TV network serving US hospitals. As principal, Ms. Lambert acquired FM radio stations and upgraded each to become Top 100 radio market properties.
Ms. Lambert’s Washington experience includes: Chief of Staff for the Republican National Senatorial Campaign Committee, Associate Deputy Secretary for the US Department of Commerce, Deputy Assistant Secretary of the Department of Energy and Chief of Staff for Sen. Malcolm Wallop.
Ms. Lambert has a BA in political science from Simmons College and completed Harvard Business School’s Advanced Management Program. For five years, she served as President of NYC’s Bellevue Hospital’s Bellevue Association Board.